202 related articles for article (PubMed ID: 25144243)
1. The oncofetal protein IMP3: a useful marker to predict poor clinical outcome in neuroendocrine tumors of the lung.
Del Gobbo A; Vaira V; Guerini Rocco E; Palleschi A; Bulfamante G; Ricca D; Fiori S; Bosari S; Ferrero S
J Thorac Oncol; 2014 Nov; 9(11):1656-61. PubMed ID: 25144243
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer.
Findeis-Hosey JJ; Xu H
Biotech Histochem; 2012 Jan; 87(1):24-9. PubMed ID: 21838610
[TBL] [Abstract][Full Text] [Related]
3. IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence.
Massironi S; Del Gobbo A; Cavalcoli F; Fiori S; Conte D; Pellegrinelli A; Milione M; Ferrero S
Endocrine; 2017 Nov; 58(2):360-367. PubMed ID: 28210937
[TBL] [Abstract][Full Text] [Related]
4. Promyelocytic leukemia zinc finger and histone H1.5 differentially stain low- and high-grade pulmonary neuroendocrine tumors: a pilot immunohistochemical study.
Hechtman JF; Beasley MB; Kinoshita Y; Ko HM; Hao K; Burstein DE
Hum Pathol; 2013 Jul; 44(7):1400-5. PubMed ID: 23416030
[TBL] [Abstract][Full Text] [Related]
5. IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes.
Del Gobbo A; Morotti A; Colombo AE; Vaira V; Ercoli G; Pesenti C; Bonaparte E; Guerini-Rocco E; Di Cristofori A; Locatelli M; Palleschi A; Ferrero S
Med Oncol; 2017 Dec; 35(1):2. PubMed ID: 29209838
[TBL] [Abstract][Full Text] [Related]
6. Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors.
Igarashi T; Jiang SX; Kameya T; Asamura H; Sato Y; Nagai K; Okayasu I
Mod Pathol; 2004 Oct; 17(10):1259-67. PubMed ID: 15154011
[TBL] [Abstract][Full Text] [Related]
7. Alterations in the expression of p53, KLF4, and p21 in neuroendocrine lung tumors.
Naranjo Gómez JM; Bernal JF; Arranz PG; Fernández SL; Roman JJ
Arch Pathol Lab Med; 2014 Jul; 138(7):936-42. PubMed ID: 24978920
[TBL] [Abstract][Full Text] [Related]
8. High-grade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not.
Findeis-Hosey JJ; Huang J; Li F; Yang Q; McMahon LA; Xu H
Hum Pathol; 2011 Jun; 42(6):867-72. PubMed ID: 21292308
[TBL] [Abstract][Full Text] [Related]
9. IMP3 Immunohistochemical Expression Remains Consistent Among All Grades of Gastrointestinal Neuroendocrine Tumors.
Agostini-Vulaj D; Whitney-Miller CL; Gonzalez RS; McMahon LA; Findeis-Hosey JJ
Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):288-293. PubMed ID: 27438513
[TBL] [Abstract][Full Text] [Related]
10. CXCL12 expression is a bona fide predictor of recurrence in lung neuroendocrine tumours; a multicentric study with emphasis on atypical carcinoids - a short report.
Del Gobbo A; Fusco N; Barella M; Ercoli G; Sciarra A; Palleschi A; Pagni F; Marchiò C; Papotti M; Ferrero S
Cell Oncol (Dordr); 2018 Dec; 41(6):687-691. PubMed ID: 30182340
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.
Yoxtheimer LM; Heymann JJ; Cohen C; Rao RA; Goyal A; Siddiqui MT
Diagn Cytopathol; 2018 Dec; 46(12):1010-1014. PubMed ID: 30284410
[TBL] [Abstract][Full Text] [Related]
12. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
[TBL] [Abstract][Full Text] [Related]
13. Malignancy-associated X chromosome allelic losses in foregut endocrine neoplasms: further evidence from lung tumors.
D'Adda T; Bottarelli L; Azzoni C; Pizzi S; Bongiovanni M; Papotti M; Pelosi G; Maisonneuve P; Antonetti T; Rindi G; Bordi C
Mod Pathol; 2005 Jun; 18(6):795-805. PubMed ID: 15578070
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of estrogen and progesterone receptors in primary pulmonary neuroendocrine tumors.
Sica G; Wagner PL; Altorki N; Port J; Lee PC; Vazquez MF; Saqi A
Arch Pathol Lab Med; 2008 Dec; 132(12):1889-95. PubMed ID: 19061285
[TBL] [Abstract][Full Text] [Related]
15. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
Swarts DR; Ramaekers FC; Speel EJ
Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
[TBL] [Abstract][Full Text] [Related]
16. Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications.
Cagle PT; el-Naggar AK; Xu HJ; Hu SX; Benedict WF
Am J Pathol; 1997 Feb; 150(2):393-400. PubMed ID: 9033254
[TBL] [Abstract][Full Text] [Related]
17. Forkhead box A2 transcription factor is expressed in all types of neuroendocrine lung tumors.
Khoor A; Stahlman MT; Johnson JM; Olson SJ; Whitsett JA
Hum Pathol; 2004 May; 35(5):560-4. PubMed ID: 15138929
[TBL] [Abstract][Full Text] [Related]
18. Neural cell adhesion molecules (NCAM) and NCAM-PSA expression in neuroendocrine lung tumors.
Lantuejoul S; Moro D; Michalides RJ; Brambilla C; Brambilla E
Am J Surg Pathol; 1998 Oct; 22(10):1267-76. PubMed ID: 9777989
[TBL] [Abstract][Full Text] [Related]
19. Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids.
Pelosi G; Scarpa A; Puppa G; Veronesi G; Spaggiari L; Pasini F; Maisonneuve P; Iannucci A; Arrigoni G; Viale G
Cancer; 2005 Mar; 103(6):1154-64. PubMed ID: 15712207
[TBL] [Abstract][Full Text] [Related]
20. Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung.
Song J; Li M; Tretiakova M; Salgia R; Cagle PT; Husain AN
Arch Pathol Lab Med; 2010 Nov; 134(11):1702-5. PubMed ID: 21043826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
